Axel Dignass
Overview
Explore the profile of Axel Dignass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
6142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abushamma S, Yadete T, Nero N, Falloon K, Parker C, Abreu M, et al.
J Crohns Colitis
. 2025 Mar;
PMID: 40066499
Background And Aims: Over 10% of patients with Crohn's disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn's disease...
2.
Dignass A, Blumenstein I, Schwedhelm C, Strassen K, Kunk L, Marquardt S, et al.
United European Gastroenterol J
. 2025 Jan;
PMID: 39878360
Background: The treatment landscape for active ulcerative colitis is rapidly evolving and current real-world evidence on response to advanced therapy is limited. This study aimed to determine indicators of inadequate...
3.
Sands B, Rubin D, Loftus Jr E, Wolf D, Panaccione R, Colombel J, et al.
Am J Gastroenterol
. 2025 Jan;
PMID: 39773524
Introduction: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during...
4.
Misselwitz B, Zeissig S, Schreiber S, Dignass A
Inn Med (Heidelb)
. 2025 Jan;
66(1):3-14.
PMID: 39747696
Background: The treatment options for chronic inflammatory bowel diseases (IBD) have been greatly expanded due to a better understanding of the underlying pathogenesis. A total of five classes of advanced...
5.
Rubin D, Allegretti J, Panes J, Shipitofsky N, Yarandi S, Huang K, et al.
Lancet
. 2024 Dec;
405(10472):33-49.
PMID: 39706209
Background: Interleukin-23 inhibition is effective in treating ulcerative colitis. Guselkumab is a dual-acting, human IgG1, interleukin-23p19 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64. We aimed to...
6.
Estevinho M, Roseira J, Teixeira P, Dignass A, Magro F
Dig Liver Dis
. 2024 Dec;
PMID: 39672772
Histologic mucosal healing (HMH) has emerged as a crucial target in managing inflammatory bowel disease, complementing the established goal of endoscopic mucosal healing. This review evaluates the significance of HMH...
7.
Sands B, DHaens G, Clemow D, Irving P, Johns J, Hunter Gibble T, et al.
Inflamm Bowel Dis
. 2024 Oct;
PMID: 39448057
Background: Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, has demonstrated induction of clinical remission at week 12 with maintenance through week 104 in patients with moderately-to-severely active ulcerative colitis (UC). Results...
8.
Dignass A, Ainsworth C, Hartz S, Dunnewind N, Redondo I, Sapin C, et al.
Adv Ther
. 2024 Oct;
41(12):4446-4462.
PMID: 39404996
Introduction: This study aimed to compare the efficacy and safety of biologics and small molecules for treatment of adults with moderately-to-severely active ulcerative colitis (UC). Methods: A systematic literature review...
9.
Moreira P, Dignass A, Estevinho M, Portal F, Mendes J, Santiago M, et al.
United European Gastroenterol J
. 2024 Oct;
12(9):1280-1291.
PMID: 39391955
Longstanding disease control in Crohn's disease (CD) is challenging and requires understanding treatment efficacy and outcomes assessment. With multiple novel therapeutic options, rigorous evaluation of outcomes in randomized controlled trials...
10.
Parigi T, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, et al.
United European Gastroenterol J
. 2024 Oct;
12(9):1266-1279.
PMID: 39367753
Background: Mucosal healing (MH) is an established treatment goal in inflammatory bowel disease (IBD). However, various definitions of MH exist. We aimed to identify how MH is defined in randomized...